

# Cytochrome *bd*-Dependent Bioenergetics and Antinitrosative Defenses in *Salmonella* Pathogenesis

Jessica Jones-Carson,<sup>a</sup> Maroof Husain,<sup>b</sup> Lin Liu,<sup>b</sup> David J. Orlicky,<sup>c</sup> Andrés Vázquez-Torres<sup>b,d</sup>

Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, Colorado, USA<sup>a</sup>; Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA<sup>b</sup>; Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado, USA<sup>c</sup>; Veterans Affairs Eastern Colorado Health Care System, Denver, Colorado, USA<sup>d</sup>

**ABSTRACT** In the course of an infection, *Salmonella enterica* occupies diverse anatomical sites with various concentrations of oxygen (O<sub>2</sub>) and nitric oxide (NO). These diatomic gases compete for binding to catalytic metal groups of quinol oxidases. *Enterobacteriaceae* express two evolutionarily distinct classes of quinol oxidases that differ in affinity for O<sub>2</sub> and NO as well as stoichiometry of H<sup>+</sup> translocated across the cytoplasmic membrane. The investigations presented here show that the dual function of bacterial cytochrome *bd* in bioenergetics and antinitrosative defense enhances *Salmonella* virulence. The high affinity of cytochrome *bd* for O<sub>2</sub> optimizes respiratory rates in hypoxic cultures, and thus, this quinol oxidase maximizes bacterial growth under O<sub>2</sub>-limiting conditions. Our investigations also indicate that cytochrome *bd*, rather than cytochrome *bo*, is an intrinsic component of the adaptive antinitrosative toolbox of *Salmonella*. Accordingly, induction of cytochrome *bd* helps *Salmonella* grow and respire in the presence of inhibitory NO. The combined antinitrosative defenses of cytochrome *bd* and the flavohemoglobin Hmp account for a great part of the adaptations that help *Salmonella* recover from the antimicrobial activity of NO. Moreover, the antinitrosative defenses of cytochrome *bd* and flavohemoglobin Hmp synergize to promote *Salmonella* growth in systemic tissues. Collectively, our investigations indicate that cytochrome *bd* is a critical means by which *Salmonella* resists the nitrosative stress that is engendered in the innate response of mammalian hosts while it concomitantly allows for proper O<sub>2</sub> utilization in tissue hypoxia.

**IMPORTANCE** It is becoming quite apparent that metabolism is critically important to the virulence potential of pathogenic microorganisms. Bacterial cells use a variety of terminal electron acceptors to power electron transport chains and metabolic processes. Of all the electron acceptors available to bacteria, utilization of O<sub>2</sub> yields the most energy while diversifying the type of substrates that a pathogen can use. Recent investigations have demonstrated important roles for *bd*-type quinol oxidases with high affinity for O<sub>2</sub> in bacterial pathogenesis. The investigations presented here have revealed that cytochrome *bd* potentiates virulence of a clinically relevant bacterial pathogen by fueling bioenergetics of prokaryotic cells while protecting the respiratory chain against NO toxicity. The adaptive antinitrosative defenses afforded by cytochrome *bd* synergize with other NO-detoxifying systems to preserve cellular bioenergetics, thereby promoting bacterial virulence in tissue hypoxia.

Received 8 November 2016 Accepted 21 November 2016 Published 20 December 2016

**Citation** Jones-Carson J, Husain M, Liu L, Orlicky DJ, Vázquez-Torres A. 2016. Cytochrome *bd*-dependent bioenergetics and antinitrosative defenses in *Salmonella* pathogenesis. mBio 7(6):e02052-16. doi:10.1128/mBio.02052-16.

**Editor** Nancy E. Freitag, University of Illinois at Chicago

**Copyright** © 2016 Jones-Carson et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Andrés Vázquez-Torres, [andres.vazquez-torres@ucdenver.edu](mailto:andres.vazquez-torres@ucdenver.edu).

This article is a direct contribution from a Fellow of the American Academy of Microbiology. External solicited reviewers: Anthony Richardson, University of Pittsburgh; Andreas Bäuml, University of California, Davis.

*Salmonella enterica* serovar Typhimurium is a common cause of nontyphoidal salmonellosis in humans and domestic animals. In most healthy individuals, nontyphoidal *Salmonella* infections acquired from diverse vertebrate hosts via the fecal/oral route present as self-limiting gastroenteritis. Nonetheless, in immunocompromised people bearing defects in CD4<sup>+</sup> T cell immunity or gamma interferon (IFN- $\gamma$ ) signaling, diverse strains of nontyphoidal *Salmonella* can cause life-threatening extraintestinal infections (1–3). *Salmonella* suffers the cytotoxicity of cationic peptides, as well as reactive oxygen and nitrogen species that are generated in the host response of vertebrate animals and humans. Nitric oxide (NO) is one of the most studied anti-*Salmonella* effectors of the innate response in mammalian cells (4). The oxida-

tion of the guanidino group of L-arginine by the enzymatic activity of NO synthases generates NO and L-citrulline (5). Reactions of NO with superoxide, molecular oxygen (O<sub>2</sub>), iron, or low-molecular-weight thiols produce an amalgam of antimicrobial reactive nitrogen species that include peroxyxynitrite, nitrogen dioxide, dinitrogen trioxide, and S-nitrosothiols. A collection of reactive nitrogen species can independently be generated upon the condensation of two molecules of acidified nitrite in the stomach and phagosomal lumen of macrophages (6–10). NO and its oxidative and nitrosative congeners exert antimicrobial activity against diverse eukaryotic and prokaryotic organisms. Cytochrome *bd*, DNA, lipoamide-dependent lipoamide dehydrogenase, and the regulatory proteins DksA and SsrB are some of the

few biomolecules known to be modified in *Salmonella* undergoing nitrosative stress (11–15).

Despite the potent antimicrobial activity that NO can exert against *Salmonella*, this intracellular pathogen tolerates remarkably well the nitrosative stress engendered in the innate host response (8, 16). Diverse antinitrosative defenses help *Salmonella* cope with NO and its oxidative by-products. For example, the low-molecular-weight thiols homocysteine and glutathione scavenge reactive nitrogen species, whereas the denitrosylase activity of the flavohemoglobin Hmp detoxifies NO to nitrate ( $\text{NO}_3^-$ ) (17–19). The combined actions of low-molecular-weight thiols and Hmp protect *Salmonella* against the nitrosative stress engendered in the innate host response of human and murine macrophages (20–24). Not only does *Salmonella* tolerate NO-mediated host defenses, but these pathogens can also take advantage of the redox properties of nitrogen oxides to colonize the gastrointestinal tract. For example, terminal cytochromes such as nitrate reductases energize cytoplasmic membranes by utilizing NO oxidative products as terminal electron acceptors (25).

Reduction of  $\text{O}_2$  to water is the canonical function of aerobic terminal cytochromes of the electron transport chain, a process that generates an electrochemical gradient across cytoplasmic membranes and powers transport systems and ATP synthesis. *Salmonella* expresses two evolutionarily distinct classes of quinol oxidases. Cytochrome *bo*, a member of the cytochrome *c* oxidase family, is encoded in the *cyoABCD* operon, whereas cytochrome *bd* and cytochrome *bd-II* are encoded in the *cydAB* and *cyxAB* operons, respectively. Cytochrome *bd* and cytochrome *bd-II* contain heme *d* in place of the  $\text{Cu}_B$  atom that occupies the catalytic site of cytochrome *bo* (26). Although less efficient than cytochrome *bo*, cytochrome *bd* also participates in the bioenergetics of the bacterial cell (26). The expression of cytochrome *bd* in *S. enterica*, *Klebsiella pneumoniae*, *Mycobacterium tuberculosis*, *Shigella flexneri*, group B *Streptococcus*, *Listeria monocytogenes*, and *Bacteroides* suggests a possible role for this quinol oxidase in bacterial pathogenesis (27). Accordingly, cytochrome *bd* promotes gastrointestinal and systemic fitness of *Citrobacter rodentium* and *S. enterica* serovar Typhimurium, respectively (28–30).

Expression of cytochrome *bd* in *E. coli*, *Staphylococcus aureus*, *Bacillus subtilis*, and *M. tuberculosis* in response to NO and the nitrosylation of the heme *d* in cytochrome *bd* of *Salmonella* raise the interesting possibility that, in addition to fueling the bioenergetics of the cell, cytochrome *bd* may be part of the antinitrosative arsenal of several pathogenic microorganisms (11, 31–35). This idea is suggested further by the fact that  $\Delta\text{cydAB}$  *E. coli* and  $\Delta\text{fur}$  *Salmonella*, a strain that harbors low concentrations of cytochrome *bd*, are hypersusceptible to the bacteriostatic activity of chemically generated NO (16, 31, 36). However, given the copious antinitrosative defenses available to pathogenic bacteria (4), it remains uncertain whether the NO-detoxifying activity of cytochrome *bd* contributes to bacterial virulence. The following investigations have explored the extent to which cytochrome *bd* contributes to the antinitrosative defenses of *Salmonella* in culture and murine models of infection.


## RESULTS

**Contribution of quinol oxidases to *Salmonella* virulence.** *Salmonella* expresses two major terminal quinol oxidases encoded within *cyoABCD* and *cydAB* operons. Compared to *cydAB*-encoded cytochrome *bd*, cytochrome *bo* has lower affinity for  $\text{O}_2$

and NO but greater capacity to translocate protons across the cytoplasmic membrane (27, 36). Given the pronounced differences between these two quinol oxidases, we compared the capacities of  $\Delta\text{cyoABCD}$  and  $\Delta\text{cydAB}$  mutants to colonize the gastrointestinal tract of streptomycin-treated C3H/HeN mice. Similar amounts of  $\Delta\text{cyoABCD}$  and  $\Delta\text{cydAB}$  *Salmonella* were shed in feces of C3H/HeN mice compared to control mice infected with an isogenic wild-type strain (Fig. 1A). With the exception of the  $\Delta\text{cydAB}$  mutant, which was recovered in lower numbers in colon,  $\Delta\text{cyoABCD}$ - and  $\Delta\text{cydAB}$ -deficient *Salmonella* appeared to be as capable as wild-type bacteria in colonizing the small and large intestines of streptomycin-treated C3H/HeN mice 3 days after oral (p.o.) inoculation. All strains tested also induced similar levels of inflammation in ceca of infected animals as indicated by the presence of edema in the submucosa, infiltration of polymorphonuclear cells in the lamina propria, and depletion of goblet cells (Fig. 1C and D). Despite these similarities, some differences in histopathology were noted. For instance, ceca of  $\Delta\text{cyoABCD}$  *Salmonella*-infected mice contained fewer polymorphonuclear cells than wild-type controls, whereas the ceca of mice infected with  $\Delta\text{cydAB}$  *Salmonella* contained more goblet cells than controls infected with either wild-type or  $\Delta\text{cyoABCD}$  *Salmonella*. Collectively, our investigations are consistent with recently published data that showed the apparent dispensability of cytochrome *bd* during colonization of the gut (28).

**Cytochrome *bd* contributes to *Salmonella* antinitrosative defenses.** Previous work showed that  $\Delta\text{fur}$  *Salmonella* is hypersusceptible to the bacteriostatic activity of NO generated chemically *in vitro* or enzymatically *in vivo* (16). Diminished 420-nm and 560-nm absorption peaks in cytoplasmic membranes of  $\Delta\text{fur}$  *Salmonella* indicate that this mutant harbors reduced concentrations of both cytochrome *bo* and cytochrome *bd*. To investigate a possible role of these two terminal cytochromes in the antinitrosative defenses of *Salmonella*, we compared growth rates of  $\Delta\text{cyoABCD}$  and  $\Delta\text{cydAB}$  mutants deficient in cytochrome *bo* and cytochrome *bd*, respectively, in LB broth supplemented with diethylenetriamine (DETA) or the NO donor DETA NONOate (Fig. 2A). Wild-type and  $\Delta\text{cyoABCD}$  *Salmonella* strains grew similarly in LB broth containing 5 mM DETA. The addition of 5 mM DETA NONOate, which is estimated to generate a constant flux of 5  $\mu\text{M}$  NO for the duration of the experiment, inhibited the growth of wild-type and  $\Delta\text{cyoABCD}$  bacteria to similar extents. These findings indicate that cytochrome *bo* does not constitute an important component of the antinitrosative arsenal of *Salmonella*. We also tested a  $\Delta\text{cydAB}$  mutant whose cytoplasmic membranes lack the characteristic 650-nm absorption peak of heme *d* (Fig. 2B). In contrast to wild-type and  $\Delta\text{cyoABCD}$  isogenic controls,  $\Delta\text{cydAB}$  *Salmonella* consistently grew more slowly in LB broth, suggesting that the high affinity for  $\text{O}_2$  of cytochrome *bd* improves growth of *Salmonella* in hypoxic media. *Salmonella* bearing the  $\Delta\text{cydAB}$  mutation was also hypersusceptible to the bacteriostatic activity of NO as suggested by the extended lag phase that followed DETA NONOate treatment. Cumulatively, these investigations indicate that cytochrome *bd*, rather than cytochrome *bo*, is an intrinsic constituent of the antinitrosative defenses of *Salmonella*.

**Cytochrome *bd* protects respiration against NO.** Since terminal cytochromes of the electron transport chain are some of the preferred targets of NO (4), we measured the rates of respiration in  $\Delta\text{cyoABC}$  and  $\Delta\text{cydAB}$  *Salmonella* exposed to spermine NONOate (Fig. 2C). Wild-type and  $\Delta\text{cyoABCD}$  *Salmonella* strains grown




**FIG 1** Quinol oxidases and colonization of the gastrointestinal tract by *Salmonella*. (A) Fecal shedding in streptomycin-treated C3H/HeN mice infected p.o. with wild-type (WT),  $\Delta cyoABCD$ , or  $\Delta cydAB$  *Salmonella*. (B) The *Salmonella* burden in small and large intestines was determined 3 days after infection. The solid line represents the median. (C) Histopathology of paraffin-embedded, hematoxylin-and-eosin-stained ceca isolated 3 days postinfection. Representative images ( $\times 200$  magnification) were collected as described in Materials and Methods. (D) The severity of edema in submucosa, polymorphonuclear leukocyte (PMN) infiltration in mucosa, and depletion of goblet cells was scored according to the method described by Barthel et al. (52). The data are from 5 to 10 mice. \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

to log phase in LB broth showed comparable respiratory activities. Addition of 50  $\mu\text{M}$  NO donor spermine NONOate similarly repressed the respiratory activity of wild-type and  $\Delta cyoABCD$  *Salmonella* (0.54 versus 0.52  $\mu\text{M}$   $\text{O}_2/\text{s}$ , respectively). Respiratory rates improved in both wild-type and  $\Delta cyoABCD$  *Salmonella* 3.5 min after treatment (1.3  $\mu\text{M}/\text{s}$ ) but did not reach those recorded in resting cells ( $\sim 1.90$   $\mu\text{M}/\text{s}$ ). The  $\Delta cydAB$  *Salmonella* strain respired more slowly than unstimulated wild-type or  $\Delta cyoABCD$  controls, strains that likely take advantage of the superior performance of cytochrome *bd* under hypoxia. Compared to wild-type bacteria, the respiratory activity of the  $\Delta cydAB$  mutant was considerably more sensitive to the inhibitory effects of spermine NONOate. Furthermore, in contrast to wild-type and  $\Delta cyoABCD$  *Salmonella*, the respiratory activity of  $\Delta cydAB$  *Salmonella* did not seem to improve over time after the addition of spermine NONO-

ate (0.67  $\mu\text{M}/\text{s}$ ). These findings indicate that cytochrome *bd*, but not cytochrome *bo*, affords protection to quinol oxidases against NO toxicity.

**Cytochrome *bd* and the flavohemoglobin Hmp lessen NO cytotoxicity.** Previous work identified the flavohemoglobin Hmp as the main antinitrosative defense of *Salmonella* (22). Because our investigations indicate that cytochrome *bd* is part of the antinitrosative arsenal of *Salmonella*, we deemed it important to compare the relative contributions of Hmp and cytochrome *bd* to the antinitrosative defenses of *Salmonella*. Toward this end, a  $\Delta cydAB::\text{Km}$  mutation was moved into  $\Delta hmp$  *Salmonella* strain AV0468. Differential spectrophotometry of whole bacterial cells indicates that  $\Delta hmp$  *Salmonella* expresses higher concentrations of cytochrome *bd* than wild-type controls as shown by the characteristic 650-nm heme *d* absorption peak (Fig. 3A). We initially




**FIG 2** Contribution of quinol oxidases to the antinitrosative defenses of *Salmonella*. (A) Wild-type (WT),  $\Delta cyo$ , or  $\Delta cydAB$  *Salmonella* grown overnight in LB broth was diluted to  $2 \times 10^6$  CFU/ml in fresh LB broth. Where indicated, bacterial cultures were treated with 5 mM DETA or NO donor DETA NONOate (dNO). Bacterial growth was recorded using a Bioscreen C growth analyzer at 37°C with continuous shaking. Data represent the means  $\pm$  standard errors of the means from 10 observations from two different experiments. (B) Absorption spectra of cytoplasmic membranes isolated from stationary-phase WT or  $\Delta cydAB$  *Salmonella* grown in LB broth. The inset shows a detail of the 480- to 690-nm region. (C) Effect of NO on respiration. Stationary-phase *Salmonella* was grown to an OD<sub>600</sub> of 0.5 in LB broth at 37°C in a shaker incubator. Bacterial cultures were diluted to an OD<sub>600</sub> of 0.2, and O<sub>2</sub> consumption was recorded over time. Prior to analysis, bacteria were treated with 50  $\mu M$  spermine NONOate (sNO) for 1 min. Untreated controls (C) are shown for comparison. Data are representative of three independent experiments.

tested the susceptibility of *hmp*-deficient *Salmonella* strains to 5 mM DETA NONOate; however, at this concentration the NO donor completely inhibited growth of both  $\Delta hmp$  and  $\Delta hmp \Delta cydAB::Km$  *Salmonella*. Therefore, we tested lower concentrations of DETA NONOate and the DETA parent compound. The addition of 1 mM DETA did not have much of an effect on the growth of wild-type *Salmonella* (Fig. 3B). As noted above for  $\Delta cydAB$  *Salmonella*, the  $\Delta hmp \Delta cydAB$  strain exhibited a slight but reproducible growth defect in LB broth. The addition of 1 mM DETA NONOate did not inhibit growth of wild-type *Salmonella*. However, 1 mM DETA NONOate extended in increasing order the lag phase of  $\Delta cydAB$ ,  $\Delta hmp$ , and  $\Delta hmp \Delta cydAB::Km$  mutant *Salmonella* strains. Together, our investigations indicate that both Hmp and cytochrome *bd* protect *Salmonella* against NO, although quantitatively the flavohemoglobin appears to confer the greatest protection. Because  $\Delta hmp \Delta cydAB::Km$  mutant *Salmonella* was more susceptible to NO than  $\Delta cydAB$  or  $\Delta hmp$  isogenic strains, our investigations also indicate that Hmp and cytochrome *bd* independently add to the antinitrosative arsenal of *Salmonella*.

Transcriptional analysis showed that the *cydA* operon is induced in wild-type *Salmonella* shortly after the addition of 50  $\mu M$  spermine NONOate ( $P < 0.0001$ ) (Fig. 3C). Consistent with the spectroscopic analysis shown in Fig. 3A,  $\Delta hmp$  *Salmonella* expressed higher levels of *cydA* than wild-type controls ( $P = 0.0117$ ). Although delayed compared to wild-type controls, NO also induced *cydAB* expression in  $\Delta hmp$  *Salmonella* ( $P < 0.0001$ ). Cu-

mulatively, these data indicate that cytochrome *bd* is part of the adaptive response of *Salmonella* to nitrosative stress.

**Cytochrome *bd* and Hmp independently protect the respiratory chain from the inhibitory activity of NO.** We next examined the rates of respiration of *Salmonella* strains deficient in Hmp and/or cytochrome *bd*. Wild-type *Salmonella* exposed for 1 min to 50  $\mu M$  spermine NONOate exhibited reduced respiratory activity (Fig. 3D). As shown above, wild-type *Salmonella* recovered about two-thirds of its maximal respiratory activity a few minutes after NO treatment, consistent with the stimulation of a partial adaptive response. To test if *Salmonella* can fully adapt to NO, respiratory activity was independently measured 10 min after spermine NONOate treatment. Wild-type *Salmonella* completely recovered O<sub>2</sub>-consuming capacity 10 min after spermine NONOate treatment (1.47 versus 1.45  $\mu M/s$  for nontreated and NO-treated specimens, respectively). As observed earlier (Fig. 2C), untreated  $\Delta cydAB$  *Salmonella* exhibited lower rates of respiration than wild-type controls. We also noticed that the marked reduction in respiratory activity (0.45  $\mu M/s$ ) of  $\Delta cydAB$  *Salmonella* treated with NO for 1 min was sustained for the duration of the experiment. Nonetheless, the respiratory activity of  $\Delta cydAB$  *Salmonella* recovered to the levels of untreated specimens 10 min after the addition of NO (0.70 and 0.69  $\mu M$  O<sub>2</sub>/s for untreated and NO-treated samples, respectively), suggesting that *Salmonella* can eventually adapt to nitrosative stress in the absence of cytochrome *bd*. It should be noted that the respiratory activity of  $\Delta cydAB$  *Salmonella* decreased



**FIG 3** Synergy of Hmp and cytochrome *bd* in the antinitrosative defenses of *Salmonella*. (A) Differential whole-cell spectra of wild-type (WT) and mutant *Salmonella*. The arrow shows the absorption peak of heme *d*. (B) Growth of *Salmonella* diluted to  $2 \times 10^6$  CFU/ml in LB broth after treatment with 1 mM DETA or DETA NONOate (dNO). Data represent the means  $\pm$  standard errors of the means from 10 observations from two independent experiments. (C) Expression of *cydA* in wild-type and  $\Delta hmp$  *Salmonella* exposed to 50  $\mu$ M spermine NONOate (sNO). Time after addition of NO ( $P < 0.0001$ ) and bacterial strain ( $P = 0.0117$ ) were found to statistically affect the expression of *cydA* as determined by two-way analysis of variance ( $n = 4$  from two independent days). No *cydA* mRNA was detected in  $\Delta cydAB$  *Salmonella* (not shown). (D) Effect of NO on respiration. Bacterial cells were prepared as described in the legend to Fig. 2. Where indicated, bacteria were treated with 50  $\mu$ M sNO for 1 or 10 min prior to the analysis of respiration. Untreated controls (C) are shown for comparison. Data are representative of 3 independent experiments.


after 10 min of culture, likely reflecting reduced affinity of cytochrome *bo* for O<sub>2</sub> as bacterial density increases over time.

Because the  $\Delta hmp$  mutant is highly susceptible to the antimicrobial activity of NO (Fig. 2) and because Hmp is a critical antinitrosative defense that promotes respiratory activity in Gram-negative bacteria undergoing nitrosative stress (37), we also examined the effects of NO on respiration of  $\Delta hmp$  *Salmonella* (Fig. 3C). Compared to  $\Delta cydAB$  isogenic controls, respiration of  $\Delta hmp$  *Salmonella* was more profoundly inhibited 1 min after exposure to 50  $\mu$ M spermine NONOate (0.45 versus 0.23  $\mu$ M O<sub>2</sub>/s, respectively), suggesting that Hmp is more efficient at detoxifying NO than cytochrome *bd*. Interestingly,  $\Delta hmp$  *Salmonella* recovered more than 50% respiratory activity 10 min after NO treatment (1.70 versus 0.96  $\mu$ M O<sub>2</sub>/s in untreated and NO-treated specimens, respectively), indicating the existence of Hmp-independent means to detoxify NO.

We finally quantified the O<sub>2</sub>-consuming capacity of a mutant lacking both *hmp* and *cydAB*. The  $\Delta hmp \Delta cydAB::Km$  *Salmonella* strain AV09592 suffered as much repression of O<sub>2</sub> consumption as its  $\Delta hmp$  isogenic control 1 min after the addition of 50  $\mu$ M spermine NONOate (0.20 versus 0.23  $\mu$ M O<sub>2</sub>/s, respectively). However, compared to  $\Delta hmp$  controls, the respiration of  $\Delta hmp \Delta cydAB::Km$  *Salmonella* remained more profoundly inhibited 10 min after NO treatment (1.48 versus 0.44  $\mu$ M O<sub>2</sub>/s). Together, these data indicate that cytochrome *bd* adds to the dominant NO-

detoxifying activity of the flavohemoglobin Hmp. Because the  $\Delta hmp \Delta cydAB$  mutant partially recovered its respiratory activity 10 min after NO treatment, these investigations also point to the existence of Hmp- and cytochrome *bd*-independent means to detoxify NO.

**Contribution of Hmp and cytochrome *bd* to *Salmonella* pathogenesis.** Having established that both Hmp and cytochrome *bd* protect respiration of *Salmonella* experiencing nitrosative stress, we used two murine models to examine the extent to which these two antinitrosative defenses contribute to *Salmonella* pathogenesis. First, C3H/HeN mice were inoculated intraperitoneally (i.p.) with equal numbers of wild-type and  $\Delta hmp$ ,  $\Delta cydAB$ , or  $\Delta hmp \Delta cydAB::Km$  *Salmonella*, and the competitive advantage of bacteria in the mixtures was determined by quantifying hepatic burden 5 days after infection. These investigations showed that  $\Delta hmp$  and  $\Delta cydAB$  *Salmonella* are similarly attenuated (competitive indexes of about 0.1 and  $P > 0.05$  compared to wild-type *Salmonella*) (Fig. 4A). In contrast,  $\Delta hmp \Delta cydAB::Km$  *Salmonella* had a competitive index of 0.01 compared to wild-type bacteria. The double mutant was found to be significantly more attenuated than either  $\Delta hmp$  ( $P < 0.01$ ) or  $\Delta cydAB$  ( $P < 0.001$ ) *Salmonella*. Together, these findings suggest a substantial degree of independence between Hmp and cytochrome *bd* in *Salmonella* pathogenesis. We also examined the relative contributions of Hmp and cytochrome *bd* in a live/dead model of acute *Salmonella* infection



**FIG 4** Hmp and cytochrome *bd* in *Salmonella* pathogenesis. (A) The competitive index was measured in livers of C3H/HeN mice 3 days after i.p. inoculation with 2,000 CFU of a mixture containing wild-type (WT) and equal numbers of  $\Delta$ cydAB::Km,  $\Delta$ hmp::Km, and  $\Delta$ hmp  $\Delta$ cydAB::Km *Salmonella*. \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ . (B) Survival of *Salmonella*-infected C3H/HeN mice was recorded over time after i.p. inoculation. Selected groups of mice were continuously fed water containing 500  $\mu$ g/ml of the iNOS inhibitor aminoguanidine (AG). The  $\Delta$ cydAB  $\Delta$ hmp mutant strain was found to be attenuated ( $P < 0.0001$ ) in C3H/HeN mice according to the log rank Mantel-Cox survival test. The data are from 5 to 7 mice per group.

(Fig. 4B). Strain AV09592 harboring mutations in both *hmp* and *cydAB* was significantly ( $P < 0.0001$ ) more attenuated than wild-type,  $\Delta$ hmp, or  $\Delta$ cydAB *Salmonella*. Administration of the inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine increased the virulence of  $\Delta$ hmp  $\Delta$ cydAB::Km *Salmonella*. Aminoguanidine-treated,  $\Delta$ hmp  $\Delta$ cydAB::Km *Salmonella*-infected mice died a few days after controls challenged with wild-type bacteria. Collectively, our investigations indicate that Hmp and cytochrome *bd* are important components of the antinitrosative toolbox of *Salmonella*.

## DISCUSSION

*Salmonella* must adapt to various concentrations of  $O_2$  and NO in different anatomical sites during the course of an infection. Differential utilization of quinol oxidases with distinct affinities for  $O_2$  and NO allows *Salmonella* to colonize the gastrointestinal tract and to establish infections in deep tissue (this study and reference 28). Our investigations have demonstrated that the ability of cytochrome *bd* to protect the electron transport chain against NO is a considerable component of the adaptive antinitrosative defenses of *Salmonella* in a murine model of acute systemic infection. The high affinity for NO of cytochrome *bd* ( $K_d$  [dissociation constant] of 0.55 nM) provides a molecular mechanism by which this quinol oxidase contributes to antinitrosative defenses (36). Preferential nitrosylation of cytochrome *bd* frees up cytochrome *bo* for respiration. In addition to having high affinity for NO, cytochrome *bd* dissociates faster from NO than most known cytochromes, including cytochrome *bo* (36). The fast dissociation of NO from heme *d* may explain why we noted that  $\Delta$ cyoABCD *Salmonella* expressing cytochrome *bd* maintains excellent respiratory activity in the presence of NO. Compared to cytochrome *bo*, fast dissociation of NO from heme *d* may also underlie the lower sensitivity of cytochrome *bd* to this diatomic radical. Cytochrome *bd* is resistant not just to NO but also to hydrogen sulfide (38, 39). Expression of cytochrome *bd* may therefore preserve respiratory activity in hypoxic environments in the presence of sulfide and NO.


Cytochrome *bd* may mediate antinitrosative defense through nitrosyl and nitrate pathways. According to the nitrosyl pathway, ferrous iron in heme *d* binds NO in competition with  $O_2$ . The nitrosyl ( $Fe_d^{2+}$ -NO) product resulting from this reaction dissociates with a  $K_{off}$  of  $0.133 s^{-1}$  (40). The nitrosyl pathway prevails at high  $e^-$  flux and low  $O_2$  concentrations, conditions that appear to be encountered by *Salmonella* in hypoxic systemic tissues (29). Second, according to the nitrite pathway, the oxoferryl ( $Fe_d^{4+}=\text{O}$ ) intermediate can react with NO with a second-order rate constant of  $10^5 M^{-1} s^{-1}$  (41). The  $NO_2^-$  anion formed at the catalytic site is ejected successfully from the  $Fe_d^{3+}$ - $NO_2^-$  intermediate, providing a direct mechanism for NO detoxification. The nitrite pathway, which proceeds under low  $e^-$  flux and high  $O_2$  conditions, provides a rationale for the noncompetitive inhibition of cytochrome *bd* at low NO/ $O_2$  ratios. Because the flavohemoglobin Hmp, whose enzymatic activity operates at high  $O_2$  concentrations (42), plays a role in *Salmonella* pathogenesis (22), *Salmonella* is likely to encounter host-derived NO under high  $O_2$  tensions. Therefore, it is possible that cytochrome *bd* detoxifies NO *in vivo* by the nitrite pathway. Whether cytochrome *bd* uses the nitrosyl or nitrite pathways depends on changing NO/ $O_2$  ratios during the course of the infection.

*Salmonella* encounters NO and its congeners in the gastrointestinal tract and within mononuclear phagocytic cells (8, 9, 43). *Salmonella* is remarkably resistant to the antimicrobial activity of NO generated in the innate host response (8). Reaction of reactive nitrogen species with low-molecular-weight thiols such as homocysteine and glutathione contributes to *Salmonella* pathogenesis (20, 21). *Salmonella* can also detoxify NO to nitrous oxide ( $N_2O$ ) or  $NO_3^-$  through the enzymatic activities of the anaerobic flavo-rubredoxin NorVW or the aerobic flavohemoglobin Hmp, respectively (22, 44, 45). Acute murine models of infection have shown that Hmp, not NorVW, defends *Salmonella* against nitrosative stress generated in the host (22), suggesting that aerobic

conversion of NO to NO<sub>3</sub><sup>-</sup> is a biologically relevant pathway for detoxification of host-derived NO. Our investigations indicate that, together with Hmp, cytochrome *bd* is an important component of the adaptive antinitrosative arsenal of *Salmonella in vivo*. Our biochemical and microbiological approaches suggest that Hmp is more important than cytochrome *bd* in protecting the respiratory and replicative capacity of *Salmonella* exposed to chemically generated NO. The competitive assays recorded in mice indicate, however, that both Hmp and cytochrome *bd* contribute to similar extents to *Salmonella* pathogenesis. Several reasons may explain the ranking of importance for Hmp and cytochrome *bd* as antinitrosative defenses of *Salmonella* depending on the experimental conditions tested. First, limited O<sub>2</sub> concentrations in mice might favor NO detoxification by cytochrome *bd*, whereas high P<sub>O<sub>2</sub></sub> tension in culture may favor Hmp enzymatic activity. Second, *Salmonella* may experience different O<sub>2</sub> and NO concentrations as the inflammatory response evolves over time in the course of the infection. Thereby, *Salmonella* may preferentially use Hmp or cytochrome *bd* according to the availability of O<sub>2</sub> and NO. Unique utilization of Hmp and cytochrome *bd* could explain why  $\Delta hmp \Delta cydAB::Km$  *Salmonella* is significantly more attenuated than mutants lacking *hmp* or *cydAB*. Third, it is also possible that Hmp and cytochrome *bd* may perform redundant NO detoxification at high O<sub>2</sub> tensions. Thus, the absence of both antinitrosative defenses in  $\Delta hmp \Delta cydAB::Km$  *Salmonella* accentuates susceptibility to NO.

Cytochrome *bd* may also add to *Salmonella* pathogenesis in ways that are independent of NO detoxification. The electrogenic quinol-O<sub>2</sub> oxidoreductase activity of cytochrome *bd* generates a proton motive force across the membrane that fuels oxidative phosphorylation (46). The importance of energetics in *Salmonella* pathogenesis is suggested by the observation that inhibition of iNOS did not completely restore virulence of  $\Delta hmp \Delta cydAB::Km$  *Salmonella*. Moreover, our biochemical and microbiological analyses showed that  $\Delta cydAB$  *Salmonella* has lower rates of respiration and growth than wild-type or  $\Delta cyoABCD$  controls. The high affinity of cytochrome *bd* for O<sub>2</sub> could allow *Salmonella* to colonize hypoxic areas in the host. In this sense, cytochrome *bd* promotes growth of *Salmonella* in systemic sites but seems to play a marginal role in colonization of gut mucosa (this work and references 28 and 30). These patterns likely reflect the fact that cytochrome *bd* works at a 5 to 10% O<sub>2</sub> tension in tissue but performs poorly at 0.8% O<sub>2</sub> in gut lumen (28). In addition to canonical energetic functions, the high affinity of cytochrome *bd* for O<sub>2</sub> could protect vulnerable [4Fe-4S] clusters in dehydratases and transcription factors such as fumarate-nitrate reduction regulator (FNR) from oxidative damage. Finally, cytochrome *bd* is an important source of oxidizing power that aids the DsbA-DsbB-ubiquinone complex with the formation of disulfide bonds and folding of periplasmic proteins (47). In this fashion, cytochrome *bd* could fuel DsbA-dependent folding of components of the *Salmonella* pathogenicity island 2 type III secretion system (48), a nanomachine that is essential for the intracellular replication of *Salmonella* as well as resistance of this facultative intracellular pathogen to oxygen-dependent and -independent antimicrobial host defenses.

In summary, our investigations indicate that dual functions of cytochrome *bd* in bacterial bioenergetics and antinitrosative defenses contribute to *Salmonella* pathogenesis in murine models of systemic infection (Fig. 5). Generation of electrochemical gradients across cytoplasmic membranes, oxidation and folding of



**FIG 5** Bioenergetic and antinitrosative roles of cytochrome *bd* in *Salmonella* pathogenesis. Cytochrome *bd* promotes antinitrosative defenses by ensuring respiratory activity in the presence of NO (left) and by detoxifying NO (right). At high NO/O<sub>2</sub> ratios and high electron flow, the high affinity of cytochrome *bd* for NO ensures that cytochrome *bo* is free to respire in *Salmonella* undergoing nitrosative stress. In addition, the high  $K_{off}$  of ferrous iron in heme *d* for NO allows cytochrome *bd* to reduce O<sub>2</sub> to water. 2H<sup>+</sup> and 1H<sup>+</sup> are translocated by the actions of cytochrome *bo* and cytochrome *bd*, respectively. At low NO/O<sub>2</sub> ratios and low electron flow, NO reacts with the oxoferryl intermediate in heme<sub>d</sub> of cytochrome *bd*, yielding the oxidative product nitrite (NO<sub>2</sub><sup>-</sup>). The dominant denitrosylase enzymatic activity of the flavohemoglobin Hmp detoxifies NO to NO<sub>3</sub><sup>-</sup>. Synergism between cytochrome *bd* and Hmp potentiates antinitrosative defenses of *Salmonella*. The width of the arrows represents, in this order, the hierarchical binding of NO to Hmp, cytochrome *bd*, and cytochrome *bo*.

periplasmic proteins, and detoxification of O<sub>2</sub> and NO represent some of the diverse mechanisms by which cytochrome *bd* may promote bacterial growth in inflammatory and normal tissue hypoxia.

## MATERIALS AND METHODS

**Bacterial strains.** Strains and primers used in these investigations are listed in Tables S1 and S2 in the supplemental material. Mutations were constructed following the  $\lambda$  Red recombinase system (49). In-frame deletions were verified by PCR analysis.

**Susceptibility to NO.** The effects of the polyamine diethylenetriamine (DETA) or the NO donor DETA NONOate on growth of wild-type and mutant *Salmonella* were measured spectrometrically on a Bioscreen C microbiology microtiter plate (Growth Curves USA, Piscataway, NJ). *Salmonella* cultures grown overnight in LB broth were diluted 1:500 in LB broth and treated with 5 mM NO donor DETA NONOate or the polyamine DETA control. Where indicated, some cultures were independently treated with 1 mM DETA NONOate. The half-life ( $t_{1/2}$ ) of DETA NONOate at neutral pH is about 20 h. We estimate that 5 mM DETA NONOate produced a rather stable flux of 5  $\mu$ M NO for 20 h that lasted the experiment (50). Bacterial growth was recorded as optical density at 600 nm (OD<sub>600</sub>) every 15 min, while cultures were shaken at 37°C.

**Cytochrome spectrometry.** Wild-type and mutant *Salmonella* strains grown overnight in LB broth were subcultured in LB broth to an OD<sub>600</sub> of 0.5. Inner membranes were prepared as described by Husain et al. (11). Briefly, bacterial pellets were resuspended in 10 mM EDTA, 100 mM Tris-HCl buffer, pH 8.5. Bacteria were lysed by passing the cell suspension through a French press cell disruptor (Thermo Electron Corporation, Milford, MA) 3 times at 18,000 lb/in<sup>2</sup> at a flow rate of 5 ml/min. Cell debris was removed after centrifugation at 10,000  $\times$  g for 20 min. The supernatants were then centrifuged at 200,000  $\times$  g for 1 h, and the pellets were solubilized in 75 mM K<sub>2</sub>HPO<sub>4</sub>, 150 mM KCl, 5 mM EDTA, 60 mM *N*-dodecyl-*N,N*-dimethyl-3-ammonio-1-propanesulfonate buffer, pH

6.4. Supernatants containing inner membranes were collected, and the protein concentration was assayed using the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific, Rockford, IL). The protein concentration in the specimens was adjusted to 1.5 mg/ml in 75 mM  $K_2HPO_4$ , 150 mM KCl, 5 mM EDTA, 10 mM ascorbate, and 60 mM *N*-dodecyl-*N,N*-dimethyl-3-ammonio-1-propanesulfonate buffer, pH 6.4. Absorbance spectroscopy was collected in a Cary 50 Bio UV-visible spectrophotometer. Cytochrome content also was evaluated by difference spectroscopy. Briefly, stationary-phase wild-type,  $\Delta hmp$ , and  $\Delta cydAB$  *Salmonella* strains grown overnight in LB broth were subcultured 1:100 in EG medium (E salts [1.66 mM  $MgSO_4$ , 9.5 mM citric acid monohydrate, 57 mM  $K_2HPO_4$ , 16.7 mM  $NaNH_3PO_4$ ] supplemented with 0.4% [wt/vol] glucose), pH 7.0, for 4 h. Bacterial densities were adjusted to an  $OD_{600}$  of 0.1. Some of the specimens were oxidized with 10 mM ammonium persulfate for 10 min before measuring cytochrome content by UV-visible spectroscopy. Cytochrome content in bacterial cells was estimated by recording reduced-minus-oxidized spectra.

**Transcriptional analysis.** Wild-type,  $\Delta hmp$ , or  $\Delta cydAB$  *Salmonella* strains grown overnight in LB broth were subcultured 1:100 in LB broth and grown at 37°C with shaking to an  $OD_{600}$  of 0.5. The cultures were treated with 50  $\mu$ M spermine NONOate for 3, 5, or 15 min at 37°C with shaking. Cultures were then combined 5:1 with a mixture of ice-cold phenol (5%)–ethanol (95%), incubated on ice for 10 min, and pelleted by centrifugation. RNA isolation was performed using the High Pure RNA isolation kit (Roche, Basel, Switzerland) according to the manufacturer's instructions for bacterial samples and included on-column DNase treatment. cDNA was prepared from 1  $\mu$ g total RNA using 0.45  $\mu$ M N6 random hexamer primers (Life Technologies, Carlsbad, CA) and 100 U of Moloney murine leukemia virus (MMLV) reverse transcriptase (Promega, Madison, WI). The primers and probes used for quantitative PCR (qPCR) are listed in Table S3 in the supplemental material. Reaction mixtures were prepared using TaqMan Gene Expression Master Mix (Life Technologies) and were incubated at 50°C for 2 min and then 95°C for 10 min, prior to 40 cycles of 95°C for 15 s and 57°C for 1 min. The expression of *cydA* was normalized to the expression of the *rpoD* housekeeping gene.

**O<sub>2</sub> measurements.** *Salmonella* grown overnight in LB broth was diluted 1:100 in EG medium. Bacteria were grown at 37°C in a shaker incubator until they reached an  $OD_{600}$  of 0.5. The cultures were diluted to an  $OD_{600}$  of 0.2 in EG medium and equilibrated in a shaker incubator at 37°C for 3 min before they were transferred into an air-sealed, multipoint measurement chamber equipped with an Iso-Oxy-2 O<sub>2</sub> probe. The evolution of O<sub>2</sub> in the cultures was recorded with an Apollo 4000 free radical analyzer (World Precision Instruments, Inc., Sarasota, FL). To assess the ability of the bacteria to adapt to NO, O<sub>2</sub> consumption was also studied in cultures treated for 10 min with 50  $\mu$ M spermine NONOate ( $t_{1/2}$  = 39 min at 37°C). The data are expressed as micromolar concentrations of O<sub>2</sub>.

**Bacterial virulence in mice.** Eight- to 10-week-old NRAMP1<sup>R</sup> C3H/HeN mice were bred at the animal facility of the University of Colorado School of Medicine according to Institutional Animal Care and Use Committee guidelines. C3H/HeN mice were treated with 20 mg/mouse 1 day before intragastric infection with 10<sup>8</sup> CFU of *Salmonella* prepared in phosphate-buffered saline (PBS) from overnight cultures grown in LB broth. *Salmonella* shedding was examined over time in fecal pellets. The abilities of wild-type and mutant *Salmonella* to colonize ileum, cecum, and colon were measured 5 days after infection. C3H/HeN mice were independently inoculated i.p. with ~2,000 CFU of a bacterial mixture containing equal numbers of wild-type and mutant *Salmonella* (51). After 3 days of infection, the bacterial burden in livers was quantified on LB agar plates containing the appropriate antibiotics. The competitive index was calculated according to the formula (strain 1/strain 2)<sub>output</sub>/(strain 1/strain 2)<sub>input</sub>. In addition, C3H/HeN mice were inoculated intraperitoneally with 1 × 10<sup>3</sup> to 3 × 10<sup>3</sup> CFU/mouse of wild-type or mutant *Salmonella*. Where indicated, the drinking water of selected groups of C3H/HeN

mice was supplemented with 500  $\mu$ g/ml of the iNOS-specific inhibitor aminoguanidine. The survival of *Salmonella*-infected mice was recorded over time.

**Histopathology.** Cecae were scored for submucosal edema, neutrophil infiltration into the lamina propria, and goblet cell number per 400× field as described previously (52). Ten fields per animal per tissue were examined. Images demonstrating representative fields were captured on an Olympus BX51 microscope equipped with a 4-megapixel Macrofire digital camera (Optronics, Goleta, CA) using the PictureFrame application 2.3 (Optronics). Composite images were assembled with the use of Adobe Photoshop. All images in the composite were handled identically.

**Statistical analysis.** One-way analysis of variance, followed by a Bonferroni posttest, was used to establish statistical significance. Differences in mouse survival of *Salmonella* infection were determined by a log rank Mantel-Cox test. A *P* value of <0.05 was considered significant.

## SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.02052-16/-/DCSupplemental>.

Table S1, DOCX file, 0.1 MB.

Table S2, DOCX file, 0.04 MB.

Table S3, DOCX file, 0.04 MB.

## ACKNOWLEDGMENTS

We thank members of the Vázquez-Torres lab for discussions.

This work, including the efforts of Andrés Vázquez-Torres, was funded by the Veterans Administration (IO1 BX002073), the National Institutes of Health (R01 AI54959), and the Burroughs Wellcome Fund.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

## FUNDING INFORMATION

This work, including the efforts of Andres Vazquez-Torres, was funded by HHS|NIH|National Institute of Allergy and Infectious Diseases (NIAID) (R01 AI54959). This work, including the efforts of Andres Vazquez-Torres, was funded by VA|Veterans Affairs Eastern Colorado Healthcare System (VAECHS) (IO1 BX002073).

## REFERENCES

- de Jong R, Altare F, Haagen IA, Elferink DG, Boer T, van Breda Vriesman PJ, Kabel PJ, Draaisma JM, van Dissel JT, Kroon FP, Casanova JL, Ottenhoff TH. 1998. Severe mycobacterial and *Salmonella* infections in interleukin-12 receptor-deficient patients. *Science* 280: 1435–1438. <http://dx.doi.org/10.1126/science.280.5368.1435>.
- Kankwatira AM, Mwfulirwa GA, Gordon MA. 2004. Non-typhoidal salmonella bacteraemia—an under-recognized feature of AIDS in African adults. *Trop Doct* 34:198–200.
- McSorley SJ, Asch S, Costalonga M, Reinhardt RL, Jenkins MK. 2002. Tracking *Salmonella*-specific CD4 T cells *in vivo* reveals a local mucosal response to a disseminated infection. *Immunity* 16:365–377. [http://dx.doi.org/10.1016/S1074-7613\(02\)00289-3](http://dx.doi.org/10.1016/S1074-7613(02)00289-3).
- Henard CA, Vázquez-Torres A. 2011. Nitric oxide and *Salmonella* pathogenesis. *Front Microbiol* 2:84. <http://dx.doi.org/10.3389/fmicb.2011.00084>.
- MacMicking J, Xie QW, Nathan C. 1997. Nitric oxide and macrophage function. *Annu Rev Immunol* 15:323–350. <http://dx.doi.org/10.1146/annurev.immunol.15.1.323>.
- Duncan C, Dougall H, Johnston P, Green S, Brogan R, Leifert C, Smith L, Golden M, Benjamin N. 1995. Chemical generation of nitric oxide in the mouth from the enterosalivary circulation of dietary nitrate. *Nat Med* 1:546–551. <http://dx.doi.org/10.1038/nm0695-546>.
- McCullister BD, Myers JT, Jones-Carson J, Husain M, Bourret TJ, Vázquez-Torres A. 2007. N<sub>2</sub>O<sub>3</sub> enhances the nitrosative potential of IFN $\gamma$ -primed macrophages in response to *Salmonella*. *Immunobiology* 212:759–769. <http://dx.doi.org/10.1016/j.imbio.2007.09.019>.
- Vazquez-Torres A, Jones-Carson J, Mastroeni P, Ischiroopoulos H, Fang FC. 2000. Antimicrobial actions of the NADPH phagocyte oxidase and inducible nitric oxide synthase in experimental salmonellosis. I. Effects on



- microbial killing by activated peritoneal macrophages in vitro. *J Exp Med* 192:227–236. <http://dx.doi.org/10.1084/jem.192.2.227>.
9. Burton NA, Schürmann N, Casse O, Steeb AK, Claudi B, Zankl J, Schmidt A, Bumann D. 2014. Disparate impact of oxidative host defenses determines the fate of *Salmonella* during systemic infection in mice. *Cell Host Microbe* 15:72–83. <http://dx.doi.org/10.1016/j.chom.2013.12.006>.
  10. McKnight GM, Duncan CW, Leifert C, Golden MH. 1999. Dietary nitrate in man: friend or foe? *Br J Nutr* 81:349–358. <http://dx.doi.org/10.1017/S000711459900063X>.
  11. Husain M, Bourret TJ, McCollister BD, Jones-Carson J, Laughlin J, Vázquez-Torres A. 2008. Nitric oxide evokes an adaptive response to oxidative stress by arresting respiration. *J Biol Chem* 283:7682–7689. <http://dx.doi.org/10.1074/jbc.M708845200>.
  12. Richardson AR, Payne EC, Younger N, Karlinsey JE, Thomas VC, Becker LA, Navarre WW, Castor ME, Libby SJ, Fang FC. 2011. Multiple targets of nitric oxide in the tricarboxylic acid cycle of *Salmonella enterica* serovar Typhimurium. *Cell Host Microbe* 10:33–43. <http://dx.doi.org/10.1016/j.chom.2011.06.004>.
  13. Henard CA, Tapscott T, Crawford MA, Husain M, Doulias PT, Porwollik S, Liu L, McClelland M, Ischiropoulos H, Vázquez-Torres A. 2014. The 4-cysteine zinc-finger motif of the RNA polymerase regulator DksA serves as a thiol switch for sensing oxidative and nitrosative stress. *Mol Microbiol* 91:790–804. <http://dx.doi.org/10.1111/mmi.12498>.
  14. Husain M, Jones-Carson J, Song M, McCollister BD, Bourret TJ, Vázquez-Torres A. 2010. Redox sensor SsrB Cys<sup>203</sup> enhances *Salmonella* fitness against nitric oxide generated in the host immune response to oral infection. *Proc Natl Acad Sci U S A* 107:14396–14401. <http://dx.doi.org/10.1073/pnas.1005299107>.
  15. Schapiro JM, Libby SJ, Fang FC. 2003. Inhibition of bacterial DNA replication by zinc mobilization during nitrosative stress. *Proc Natl Acad Sci U S A* 100:8496–8501. <http://dx.doi.org/10.1073/pnas.1033133100>.
  16. Husain M, Jones-Carson J, Liu L, Song M, Saah JR, Troxell B, Mendoza M, Hassan H, Vázquez-Torres A. 2014. Ferric uptake regulator-dependent antinitrosative defenses in *Salmonella enterica* serovar Typhimurium pathogenesis. *Infect Immun* 82:333–340. <http://dx.doi.org/10.1128/IAI.01201-13>.
  17. Gardner PR, Gardner AM, Martin LA, Salzman AL. 1998. Nitric oxide dioxygenase: an enzymic function for flavohemoglobin. *Proc Natl Acad Sci U S A* 95:10378–10383. <http://dx.doi.org/10.1073/pnas.95.18.10378>.
  18. Hausladen A, Gow A, Stamler JS. 2001. Flavohemoglobin denitrosylase catalyzes the reaction of a nitroxyl equivalent with molecular oxygen. *Proc Natl Acad Sci U S A* 98:10108–10112. <http://dx.doi.org/10.1073/pnas.181199698>.
  19. Carmel-Harel O, Storz G. 2000. Roles of the glutathione- and thioredoxin-dependent reduction systems in the *Escherichia coli* and *Saccharomyces cerevisiae* responses to oxidative stress. *Annu Rev Microbiol* 54:439–461. <http://dx.doi.org/10.1146/annurev.micro.54.1.439>.
  20. De Groot MA, Testerman T, Xu Y, Stauffer G, Fang FC. 1996. Homocysteine antagonism of nitric oxide-related cytostasis in *Salmonella typhimurium*. *Science* 272:414–417. <http://dx.doi.org/10.1126/science.272.5260.414>.
  21. Song M, Husain M, Jones-Carson J, Liu L, Henard CA, Vázquez-Torres A. 2013. Low-molecular-weight thiol-dependent antioxidant and antinitrosative defenses in *Salmonella* pathogenesis. *Mol Microbiol* 87:609–622. <http://dx.doi.org/10.1111/mmi.12119>.
  22. Bang IS, Liu L, Vázquez-Torres A, Crouch ML, Stamler JS, Fang FC. 2006. Maintenance of nitric oxide and redox homeostasis by the *Salmonella* flavohemoglobin hmp. *J Biol Chem* 281:28039–28047. <http://dx.doi.org/10.1074/jbc.M605174200>.
  23. Stevanin TM, Poole RK, Demoncheaux EA, Read RC. 2002. Flavohemoglobin Hmp protects *Salmonella enterica* serovar Typhimurium from nitric oxide-related killing by human macrophages. *Infect Immun* 70:4399–4405. <http://dx.doi.org/10.1128/IAI.70.8.4399-4405.2002>.
  24. Hayden HS, Matamouros S, Hager KR, Brittnacher MJ, Rohmer L, Radey MC, Weiss EJ, Kim KB, Jacobs MA, Sims-Day EH, Yue M, Zaidi MB, Schifferli DM, Manning SD, Walson JL, Miller SI. 2016. Genomic analysis of *Salmonella enterica* serovar Typhimurium characterizes strain diversity for recent U.S. salmonellosis cases and identifies mutations linked to loss of fitness under nitrosative and oxidative stress. *mBio* 7:e00154-16. <http://dx.doi.org/10.1128/mBio.00154-16>.
  25. Vázquez-Torres A, Bäuml AJ. 2016. Nitrate, nitrite and nitric oxide reductases: from the last universal common ancestor to modern bacterial pathogens. *Curr Opin Microbiol* 29:1–8. <http://dx.doi.org/10.1016/j.mib.2015.09.002>.
  26. Borisov VB, Verkhovskiy MI. 26 August 2009, posting date. Oxygen as acceptor. *EcoSal Plus* 2009 <http://dx.doi.org/10.1128/ecosalplus.3.2.7>.
  27. Borisov VB, Forte E, Siletsky SA, Arese M, Davletshin AI, Sarti P, Giuffrè A. 2015. Cytochrome *bd* protects bacteria against oxidative and nitrosative stress: a potential target for next-generation antimicrobial agents. *Biochemistry (Mosc)* 80:565–575. <http://dx.doi.org/10.1134/S0006297915050077>.
  28. Rivera-Chávez F, Zhang LF, Faber F, Lopez CA, Byndloss MX, Olson EE, Xu G, Velázquez EM, Lebrilla CB, Winter SE, Bäuml AJ. 2016. Depletion of butyrate-producing clostridia from the gut microbiota drives an aerobic luminal expansion of *Salmonella*. *Cell Host Microbe* 19:443–454. <http://dx.doi.org/10.1016/j.chom.2016.03.004>.
  29. Lopez CA, Miller BM, Rivera-Chávez F, Velázquez EM, Byndloss MX, Chávez-Arroyo A, Lokken KL, Tsois RM, Winter SE, Bäuml AJ. 2016. Virulence factors enhance *Citrobacter rodentium* expansion through aerobic respiration. *Science* 353:1249–1253. <http://dx.doi.org/10.1126/science.aag3042>.
  30. Craig M, Sadik AY, Golubeva YA, Tidhar A, Slauch JM. 2013. Twin-arginine translocation system (*tat*) mutants of *Salmonella* are attenuated due to envelope defects, not respiratory defects. *Mol Microbiol* 89:887–902. <http://dx.doi.org/10.1111/mmi.12318>.
  31. Giuffrè A, Borisov VB, Arese M, Sarti P, Forte E. 2014. Cytochrome *bd* oxidase and bacterial tolerance to oxidative and nitrosative stress. *Biochim Biophys Acta* 1837:1178–1187. <http://dx.doi.org/10.1016/j.bbabi.2014.01.016>.
  32. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, Gennaro ML. 2005. Changes in energy metabolism of *Mycobacterium tuberculosis* in mouse lung and under *in vitro* conditions affecting aerobic respiration. *Proc Natl Acad Sci U S A* 102:15629–15634. <http://dx.doi.org/10.1073/pnas.0507850102>.
  33. Pullan ST, Gidley MD, Jones RA, Barrett J, Stevanin TM, Read RC, Green J, Poole RK. 2007. Nitric oxide in chemostat-cultured *Escherichia coli* is sensed by Fnr and other global regulators: unaltered methionine biosynthesis indicates lack of S-nitrosation. *J Bacteriol* 189:1845–1855. <http://dx.doi.org/10.1128/JB.01354-06>.
  34. Richardson AR, Dunman PM, Fang FC. 2006. The nitrosative stress response of *Staphylococcus aureus* is required for resistance to innate immunity. *Mol Microbiol* 61:927–939. <http://dx.doi.org/10.1111/j.1365-2958.2006.05290.x>.
  35. Moore CM, Nakano MM, Wang T, Ye RW, Helmann JD. 2004. Response of *Bacillus subtilis* to nitric oxide and the nitrosating agent sodium nitroprusside. *J Bacteriol* 186:4655–4664. <http://dx.doi.org/10.1128/JB.186.14.4655-4664.2004>.
  36. Mason JG, Shepherd M, Nicholls P, Dobbin PS, Dodsworth KS, Poole RK, Cooper CE. 2009. Cytochrome *bd* confers nitric oxide resistance to *Escherichia coli*. *Nat Chem Biol* 5:94–96. <http://dx.doi.org/10.1038/nchembio.135>.
  37. Stevanin TM, Ioannidis N, Mills CE, Kim SO, Hughes MN, Poole RK. 2000. Flavohemoglobin Hmp affords inducible protection for *Escherichia coli* respiration, catalyzed by cytochromes *bo'* or *bd*, from nitric oxide. *J Biol Chem* 275:35868–35875. <http://dx.doi.org/10.1074/jbc.M002471200>.
  38. Forte E, Borisov VB, Falabella M, Colaço HG, Tinajero-Trejo M, Poole RK, Vicente JB, Sarti P, Giuffrè A. 2016. The terminal oxidase cytochrome *bd* promotes sulfide-resistant bacterial respiration and growth. *Sci Rep* 6:23788. <http://dx.doi.org/10.1038/srep23788>.
  39. Korshunov S, Imlay KRC, Imlay JA. 2016. The cytochrome *bd* oxidase of *Escherichia coli* prevents respiratory inhibition by endogenous and exogenous hydrogen sulfide. *Mol Microbiol* 101:62–77. <http://dx.doi.org/10.1111/mmi.13372>.
  40. Borisov VB, Forte E, Sarti P, Brunori M, Konstantinov AA, Giuffrè A. 2007. Redox control of fast ligand dissociation from *Escherichia coli* cytochrome *bd*. *Biochem Biophys Res Commun* 355:97–102. <http://dx.doi.org/10.1016/j.bbrc.2007.01.118>.
  41. Borisov VB, Forte E, Sarti P, Brunori M, Konstantinov AA, Giuffrè A. 2006. Nitric oxide reacts with the ferryl-oxo catalytic intermediate of the CuB-lacking cytochrome *bd* terminal oxidase. *FEBS Lett* 580:4823–4826. <http://dx.doi.org/10.1016/j.febslet.2006.07.072>.
  42. Gardner PR, Gardner AM, Martin LA, Dou Y, Li T, Olson JS, Zhu H, Riggs AF. 2000. Nitric-oxide dioxygenase activity and function of flavohemoglobins. Sensitivity to nitric oxide and carbon monoxide inhibition.

- J Biol Chem 275:31581–31587. <http://dx.doi.org/10.1074/jbc.M004141200>.
43. Khan SA, Stribos PJ, Everest P, Moss D, Stratford R, Mastroeni P, Allen J, Servos S, Charles IG, Dougan G, Maskell DJ. 2001. Early responses to *Salmonella typhimurium* infection in mice occur at focal lesions in infected organs. *Microb Pathog* 30:29–38. <http://dx.doi.org/10.1006/mpat.2000.0405>.
  44. Mills PC, Richardson DJ, Hinton JC, Spiro S. 2005. Detoxification of nitric oxide by the flavorubredoxin of *Salmonella enterica* serovar Typhimurium. *Biochem Soc Trans* 33:198–199. <http://dx.doi.org/10.1042/BST0330198>.
  45. Crawford MJ, Goldberg DE. 1998. Role for the *Salmonella* flavohemoglobin in protection from nitric oxide. *J Biol Chem* 273:12543–12547. <http://dx.doi.org/10.1074/jbc.273.20.12543>.
  46. Puustinen A, Finel M, Haltia T, Gennis RB, Wikström M. 1991. Properties of the two terminal oxidases of *Escherichia coli*. *Biochemistry* 30:3936–3942. <http://dx.doi.org/10.1021/bi00230a019>.
  47. Bader M, Muse W, Ballou DP, Gassner C, Bardwell JC. 1999. Oxidative protein folding is driven by the electron transport system. *Cell* 98:217–227. [http://dx.doi.org/10.1016/S0092-8674\(00\)81016-8](http://dx.doi.org/10.1016/S0092-8674(00)81016-8).
  48. Ellermeier CD, Slauch JM. 2004. RtsA coordinately regulates DsbA and the *Salmonella* pathogenicity island 1 type III secretion system. *J Bacteriol* 186:68–79. <http://dx.doi.org/10.1128/JB.186.1.68-79.2004>.
  49. Price-Carter M, Tingey J, Bobik TA, Roth JR. 2001. The alternative electron acceptor tetrathionate supports B12-dependent anaerobic growth of *Salmonella enterica* serovar Typhimurium on ethanolamine or 1,2-propanediol. *J Bacteriol* 183:2463–2475. <http://dx.doi.org/10.1128/JB.183.8.2463-2475.2001>.
  50. Henard CA, Vázquez-Torres A. 2012. DksA-dependent resistance of *Salmonella enterica* serovar Typhimurium against the antimicrobial activity of inducible nitric oxide synthase. *Infect Immun* 80:1373–1380. <http://dx.doi.org/10.1128/IAI.06316-11>.
  51. Beuzón CR, Méresse S, Unsworth KE, Ruíz-Albert J, Garvis S, Waterman SR, Ryder TA, Boucrot E, Holden DW. 2000. *Salmonella* maintains the integrity of its intracellular vacuole through the action of SifA. *EMBO J* 19:3235–3249. <http://dx.doi.org/10.1093/emboj/19.13.3235>.
  52. Barthel M, Hapfelmeier S, Quintanilla-Martínez L, Kremer M, Rohde M, Hogardt M, Pfeffer K, Rüssmann H, Hardt WD. 2003. Pretreatment of mice with streptomycin provides a *Salmonella enterica* serovar Typhimurium colitis model that allows analysis of both pathogen and host. *Infect Immun* 71:2839–2858. <http://dx.doi.org/10.1128/IAI.71.5.2839-2858.2003>.